...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Simultaneous determination of 17alpha-hydroxypregnenolone and 17alpha-hydroxyprogesterone in dried blood spots from low birth weight infants using LC-MS/MS.
【24h】

Simultaneous determination of 17alpha-hydroxypregnenolone and 17alpha-hydroxyprogesterone in dried blood spots from low birth weight infants using LC-MS/MS.

机译:使用LC-MS / MS同时测定低出生体重儿干血斑中的17α-羟基孕烯醇酮和17α-羟基孕酮。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

17alpha-hydroxypregnenolone (17OHPreg) has heretofore been considered to be the major cause of the false elevated 17alpha-hydroxyprogesterone (17OHP) value in the immunoassay-based newborn screening for congenital adrenal hyperplasia (CAH). To verify this point, we developed a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method that enables the simultaneous quantification of 17OHPreg and 17OHP in the dried blood filter papers and measured their blood levels in infants, especially in infants with low birth weights. Steroids were extracted from the filter papers with methanol, purified using a Strata-X cartridge, derivatized with 2-hydrazinopyridine and subjected to LC-MS/MS. Validation tests proved that this method was specific and reproducible; endogenous steroids did not interfere with the quantifications, and the intra- and inter-assay coefficients of variation were below 5.2%. The limits of quantitation were 1.0 and 0.5 ng/mL for 17OHPreg and 17OHP, respectively, when 3 disks (3 mm in diameter) of the filter papers (corresponding to 8 microL of whole blood) were used. The blood 17OHPreg level was elevated in the very low birth weight (1000-1500 g) infants and extremely low birth weight (<1000 g) infants, compared to those in the normal birth weight (>2500 g) infants (P<0.05). However, the 17OHPreg concentration was not high enough to cause the false positive results in the enzyme immunoassay-based screening, and it was considered that the false positive results come from other endogenous components rather than 17OHPreg.
机译:迄今为止,在基于免疫测定的新生儿先天性肾上腺增生(CAH)筛查中,17α-羟基孕烯醇酮(17OHPreg)一直被认为是17α-羟基孕酮(17OHP)值假增高的主要原因。为了验证这一点,我们开发了一种液相色谱-串联质谱(LC-MS / MS)方法,该方法能够同时定量干血滤纸中的17OHPreg和17OHP,并测量婴儿,尤其是低血脂婴儿的血药浓度。出生体重。用甲醇从滤纸中提取类固醇,使用Strata-X柱纯化,用2-肼基吡啶衍生并进行LC-MS / MS。验证测试证明该方法具有特异性和可重复性。内源性类固醇不干扰定量,测定内和测定间变异系数低于5.2%。当使用3盘(直径3 mm)滤纸(相当于8微升全血)时,17OHPreg和17OHP的定量限分别为1.0和0.5 ng / mL。与正常出生体重(> 2500 g)的婴儿相比,极低出生体重(1000-1500 g)的婴儿和极低出生体重(<1000 g)的婴儿的血液17OHPreg水平升高(P <0.05) 。然而,17OHPreg的浓度不足以在基于酶免疫测定的筛选中引起假阳性结果,并且认为假阳性结果来自其他内源性成分而不是17OHPreg。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号